Samsrita Labs Limited has submitted its quarterly compliance statement to stock exchanges, confirming no deviation or variation in the use of proceeds raised through preferential issue for the quarter ended December 31, 2025. The statement was filed in accordance with Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Fund Raising Details

The company successfully raised ₹339.10 lakhs through preferential issue on July 18, 2025. The funds were allocated across four specific objectives to support the company's operational and strategic requirements.

Fund Utilization Breakdown

The company has provided a detailed breakdown of fund utilization across the originally planned objectives, demonstrating adherence to the stated purposes without any modifications.

Compliance and Governance

The Audit Committee of Samsrita Labs Limited reviewed the fund utilization statement on February 6, 2026, confirming no deviations from the original allocation plan. The statement indicates that no monitoring agency oversight was required for this preferential issue.

Key compliance highlights include:

• No deviation or variation in use of raised funds
• No modifications to original objects or allocations
• Proper audit committee review and approval
• Timely regulatory filing within prescribed timelines

Current Status

The company has fully utilized funds allocated for working capital requirements and loan repayments to promoter directors. Investment in new projects remains unutilized, while general corporate purposes show partial utilization of ₹20.83 lakhs against the allocated ₹66.23 lakhs. The statement was signed by Krishnam Raju Kalidindi, Chairman and Wholetime Director, confirming the accuracy of the reported fund utilization.

Samsrita labs Limited reported a substantial widening of losses for the third quarter of FY26, with net loss reaching ₹335.56 lakhs compared to ₹4.05 lakhs in the corresponding quarter of the previous year. The healthcare sector company's financial performance was significantly impacted by a major asset write-off during the quarter ended December 31, 2025.

Financial Performance Overview

The company's quarterly results showed a dramatic deterioration across key metrics:

Nine-Month Performance

The nine-month period ended December 31, 2025, showed similarly concerning trends:

Major Asset Write-off

The primary driver of the increased losses was a significant write-off of intangible assets under development worth ₹3,25,95,369. The company stated that this adjustment was necessitated by technological obsolescence, as the underlying patents are no longer expected to provide future economic benefits. This write-off was recognized in the Statement of Profit and Loss for the quarter and represents a substantial one-time charge affecting the company's financial performance.

Operational Metrics

Samsrita Labs reported no revenue from operations during both the current quarter and the corresponding previous period. The company's paid-up equity share capital stood at ₹2,274.97 lakhs as of December 31, 2025, compared to ₹1,480.87 lakhs in the previous year, indicating a capital increase during the period.

Consolidated Results

On a consolidated basis, the company reported a net loss of ₹293.94 lakhs for Q3 FY26, which was partially offset by a share of profit from associates and joint ventures amounting to ₹41.62 lakhs. The consolidated nine-month loss stood at ₹771.31 lakhs. The consolidated results include contributions from associate companies Krisani Biosciences Private Limited and Qrops Advisory Services Private Limited.

Regulatory Compliance

The unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 6, 2026. The results have been prepared in accordance with Indian Accounting Standards (Ind AS) and have undergone limited review by statutory auditors MGR & CO, Chartered Accountants.